ProfileGDS5678 / 1433433_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 77% 77% 76% 77% 79% 78% 77% 75% 77% 72% 77% 78% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.342478
GSM967853U87-EV human glioblastoma xenograft - Control 25.2945477
GSM967854U87-EV human glioblastoma xenograft - Control 35.2850377
GSM967855U87-EV human glioblastoma xenograft - Control 45.2722776
GSM967856U87-EV human glioblastoma xenograft - Control 55.2797177
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.3465179
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.2887478
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.1749677
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0430675
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.2887777
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.5859572
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.2841777
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2904278
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.9295575